Literature DB >> 21346057

Pertussis serodiagnosis in Belgium from 1990 to 2009.

Muriel Vincent1, Caroline Rodeghiero, Romain Eylenbosch, Yvan Mans, Jeannine Swalus-Steenhouwer, Denis Piérard, Kris Huygen, Raymond Vanhoof.   

Abstract

Diagnosis of pertussis by culture and PCR is most sensitive when performed on nasopharyngeal specimens collected <2 weeks and <3 weeks, respectively, after the onset of clinical disease. Conversely, serological testing allows the diagnosis of patients (mostly adults) with less typical whooping cough symptoms, for whom clinical samples are often collected at later time points. Here, we report on a 20-year serodiagnostic survey of pertussis in Belgium from 1990 to 2009. In total, 13,163 patients were analyzed for Bordetella pertussis-specific antibodies by agglutination, complement fixation, immunofluorescence, and ELISA. The number of positive pertussis cases detected by serodiagnosis ranged between 50 and 150 annually. The mean age of positive cases increased from 9.9 years in 1990 to 33.9 years in 2009. Whereas from 1990 to 2003, children and young adolescents made up the majority of cases, from 2004 onwards, cases were detected in all age groups and the distribution became bimodal, with a first peak at the age of 10 to 20 years and a second at the age of 35 to 50 years. In contrast, patients diagnosed since 2001 by PCR and/or culture were mostly children younger than 1 year of age. Despite extensive childhood vaccination campaigns, whooping cough is still present in Belgium. Our findings confirm the potential role of adults in the continued transmission of pertussis and strongly warrant booster or cocoon vaccinations in older age groups.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346057      PMCID: PMC3122568          DOI: 10.1128/CVI.00003-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  25 in total

1.  Vaccination coverage estimates by EPI cluster sampling survey of children (18-24 months) in Flanders, Belgium.

Authors:  A Vellinga; A M Depoorter; P Van Damme
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

2.  Vaccinate the village.

Authors:  Alfred Demaria; Susan M Lett
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

3.  Failure of physicians to consider the diagnosis of pertussis in children.

Authors:  S Deeks; G De Serres; N Boulianne; B Duval; L Rochette; P Déry; S Halperin
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

4.  Pertussis disease burden in the household: how to protect young infants.

Authors:  S C de Greeff; F R Mooi; A Westerhof; J M M Verbakel; M F Peeters; C J Heuvelman; D W Notermans; L H Elvers; J F P Schellekens; H E de Melker
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

5.  Deaths from pertussis are underestimated in England.

Authors:  N S Crowcroft; N Andrews; C Rooney; M Brisson; E Miller
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

6.  Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study.

Authors:  Dorothy Xing; Carl Heinz Wirsing von König; Penny Newland; Marion Riffelmann; Bruce D Meade; Michael Corbel; Rose Gaines-Das
Journal:  Clin Vaccine Immunol       Date:  2008-12-24

7.  Molecular typing of Bordetella pertussis isolates recovered from Belgian children and their household members.

Authors:  Iris De Schutter; Anne Malfroot; Isidoor Dab; Nathalie Hoebrekx; Gaëtan Muyldermans; Denis Piérard; Sabine Lauwers
Journal:  Clin Infect Dis       Date:  2003-05-21       Impact factor: 9.079

8.  Transmission of Bordetella pertussis to young infants.

Authors:  Aaron M Wendelboe; Elisabeth Njamkepo; Antoine Bourillon; D Daniel Floret; Joel Gaudelus; Michael Gerber; Emmanuel Grimprel; David Greenberg; Scott Halperin; Johannes Liese; Flor Muñoz-Rivas; Remy Teyssou; Nicole Guiso; Annelies Van Rie
Journal:  Pediatr Infect Dis J       Date:  2007-04       Impact factor: 2.129

Review 9.  What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories.

Authors:  N Guiso; G Berbers; N K Fry; Q He; M Riffelmann; C H Wirsing von König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-11       Impact factor: 3.267

10.  International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.

Authors:  M L Tondella; G M Carlone; N Messonnier; C P Quinn; B D Meade; D L Burns; J D Cherry; N Guiso; E L Hewlett; K M Edwards; D Xing; A Giammanco; C H Wirsing von König; L Han; L Hueston; J B Robbins; M Powell; C M Mink; J T Poolman; S W Hildreth; F Lynn; A Morris
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

View more
  4 in total

1.  Serum immunoglobulin G analysis to establish a delayed diagnosis of chronic cough due to Bordetella pertussis.

Authors:  Jonathan M Bock; Charles C Burtis; David M Poetker; Joel H Blumin; Michael O Frank
Journal:  Otolaryngol Head Neck Surg       Date:  2011-10-10       Impact factor: 3.497

2.  Pertussis diagnosis in Belgium: results of the National Reference Centre for Bordetella anno 2015.

Authors:  H Martini; C Rodeghiero; C VAN DEN Poel; M Vincent; D Pierard; K Huygen
Journal:  Epidemiol Infect       Date:  2017-06-05       Impact factor: 4.434

3.  Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012.

Authors:  K Huygen; C Rodeghiero; D Govaerts; I Leroux-Roels; P Melin; M Reynders; S Van Der Meeren; S Van Den Wijngaert; D Pierard
Journal:  Epidemiol Infect       Date:  2013-09-27       Impact factor: 4.434

4.  Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.

Authors:  Henri Laurichesse; Ulrich Zimmermann; Florence Galtier; Odile Launay; Xavier Duval; Patrick Richard; Christine Sadorge; Benoit Soubeyrand
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.